MedTrace Logo

Lovastatin for the Treatment of Mildly Active Rheumatoid Arthritis

NCT00302952 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 64

Last updated 2022-09-07

Study results available
· View outcomes & findings →

Summary

Rheumatoid arthritis (RA) is the most common inflammatory arthritis and a major health problem. The purpose of this study is to determine the safety and effectiveness of lovastatin for controlling inflammation in mildly active RA.

Conditions

Interventions

DRUG

Lovastatin

Two 40 mg lovastatin tablets orally once daily for a total of 12 weeks in a blinded (masked) fashion

DRUG

Placebo

Two placebo tablets orally once daily for a total of 12 weeks in a blinded (masked) fashion

Sponsors & Collaborators

  • Autoimmunity Centers of Excellence

    collaborator OTHER

  • National Institute of Allergy and Infectious Diseases (NIAID)

    lead NIH

Principal Investigators

  • Cynthia Aranow, MD · Feinstein Institute for Medical Research NS-LIJ Health System

  • Betty Diamond, MD · Feinstein Institute for Medical Research NS-LIJ Health System

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-11-06
Primary Completion
2012-04-30
Completion
2012-04-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00302952 on ClinicalTrials.gov